Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034866 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals
A Phase 2 study of HIV Infections, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT00034866: Completed Phase 2 study of HIV Infections, sponsored by Boehringer Ingelheim.
NCT00034866 is a Phase 2 study of HIV Infections that has completed, run by Boehringer Ingelheim. The registered enrollment target is 165 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034866, a Phase 2 study of HIV Infections, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to determine which of three different dose combinations of tipranavir and ritonavir, when taken with a standard approved anti-HIV drug therapy, is most effective and safe. Tipranavir is an investigational protease inhibitor which has been demonstrated to have in vitro activity against HIV-1.
Conditions Studied
Interventions
- DRUG Protease inhibitor tipranavir
Study Locations (20)
California
- Orange County Center for Special Immunology - Fountain Valley
- Living Hope Clinical Trials Inc. - Long Beach
- AHF Research Center - Los Angeles
- University of So. California / LA County USC Medical Center - Los Angeles
- ID Care, Inc. - Los Angeles
- Tower I.D. Medical Assoc., Inc. - Los Angeles
- University of California, Los Angeles Medical Center - Los Angeles
- University of California San Francisco Positive Health Program Research - San Francisco
- Pacific Horizon Medial Group - San Francisco
Florida
- (IDC) Research Institute - Altamonte Springs
- Therafirst Medical Center - Fort Lauderdale
- Jackson Medical Tower - Miami
- Steinhart Medical Associates - South Miami
- Hillsborough County Health Dept. - Tampa
- Treasure Coast Infectious Disease Consultants - Vero Beach
District of Columbia
- Georgetown University Medical Center - Washington D.C.
- Dupont Circle Physicians Group - Washington D.C.
Georgia
- AIDS Research Consortium of Atlanta - Atlanta
- Atlanta VA Medical Center, Dept. of ID - Decatur
Arizona
- Phoenix Body Positive - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2002-04 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
What the finished NCT00034866 record still lists
NCT00034866 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (63% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Protease inhibitor tipranavir is the first listed.
NCT00034866 names 20 study sites across 5 states, led by California, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00034866 about?
NCT00034866 is a clinical study titled "Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals". The purpose of this research study is to determine which of three different dose combinations of tipranavir and ritonavir, when taken with a standard approved anti-HIV drug therapy, is most effective and safe. Tipranavir is an investigational protease inhibitor which has been demonstrated to have in...
What is the current status of trial NCT00034866?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2002-04. Estimated completion is 2002-10.
What conditions does trial NCT00034866 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00034866?
The interventions under investigation include: Protease inhibitor tipranavir (DRUG).
Who is sponsoring clinical trial NCT00034866?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00034866 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00034866's enrollment target sits among peer trials
165 202nd of 542 higher than 341 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia